Figure 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

<p>Plasma concentration for copanlisib (BAY 80-6946). Plasma concentration of copanlisib (BAY 80-6946) was measured in samples from nine patients collected on cycle 1 day 15 before infusion (pre-dose) and at 0.5, 1, 2, 4, 6, 8, and 24 hours after infusion. Eight patients received copanlisib 45...

Бүрэн тодорхойлолт

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Andre L. De Souza (22819921) (author)
Бусад зохиолчид:	Matthew J. Hadfield (22819924) (author), Shaolei Lu (22819927) (author), Dragan J. Golijanin (22819930) (author), Roxanne Wood (22819933) (author), Jeannine Margolis (22819936) (author), Kate Anderson (22819939) (author), Adam J. Olszewski (15129834) (author), Sheldon L. Holder (22819942) (author), Wafik S. El-Deiry (15170575) (author), Rahul R. Aggarwal (15132918) (author), Anthony E. Mega (22819945) (author), Benedito A. Carneiro (15925723) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase I Clinical Trials Prostate Cancer Small Molecule Agents DNA-reactive agents
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Figure 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Ижил төстэй зүйлс